Feng et al., 2017
Do GLP-1 Receptor Agonists Improve Cardiovascular Health Independent of Weight Loss
Case reports that linked GLP-1s to suicidality have raised regulatory concerns and left many wondering if these medications are harming the patients they intend to help, Laurent Azoulay, PhD , a professor and William Dawson Scholar at McGill University and a senior investigator at the Jewish General Hospitals Lady Davis Institute in Montreal, Canada, told Healio
Retatrutide and Tirzepatide | Side Effects and Safety Research into tirzepatide and retatrutide has yielded substantial insights into their potential side effects, with gastrointestinal issues being the most frequently reported across studies
The findings from this study may inform the development of future therapeutic interventions, clinical practices, and policymaking, both at a local level in Australia and at a global public health level
The results for orforglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, show less dramatic weight loss than injectable medications but are still clinically meaningful, according to the manufacturer Eli Lilly